Cargando…

Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy

PURPOSE: A subset of patients treated with postprostatectomy radiation therapy for biochemical recurrence after surgery fail to respond because of microscopic disease beyond the irradiated prostate bed. This work aims to determine whether a rising interim prostate-specific antigen (PSA) during radia...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardoso, Michael, Ngo, Diana, Lim, Karen, Wong, Karen, Sidhom, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071726/
https://www.ncbi.nlm.nih.gov/pubmed/33912736
http://dx.doi.org/10.1016/j.adro.2021.100646
_version_ 1783683771096104960
author Cardoso, Michael
Ngo, Diana
Lim, Karen
Wong, Karen
Sidhom, Mark
author_facet Cardoso, Michael
Ngo, Diana
Lim, Karen
Wong, Karen
Sidhom, Mark
author_sort Cardoso, Michael
collection PubMed
description PURPOSE: A subset of patients treated with postprostatectomy radiation therapy for biochemical recurrence after surgery fail to respond because of microscopic disease beyond the irradiated prostate bed. This work aims to determine whether a rising interim prostate-specific antigen (PSA) during radiation therapy can predict the likelihood of subsequent biochemical recurrence. METHODS AND MATERIALS: Between 2010 and 2016, 185 patients had salvage radiation therapy to a dose of 68 Gy without androgen deprivation therapy for a rising PSA level after radical prostatectomy. Patients had their PSA recorded on the first day of radiation therapy and again after completing the 25th fraction (of 34 total fractions). Biochemical failure after radiation therapy was defined as a PSA value ≥0.2 ng/mL within 2 years after radiation therapy. Both univariate and multivariate Cox regression models were used for statistical analysis. Factors with a P value of <.2 in univariate analysis were then used in a multivariate analysis. RESULTS: The 2-year freedom from biochemical failure was 60% (95% confidence interval, 53%-67%). When assessing the interim PSA, 143 patients (77%) had a drop in interim PSA; of these patients, 71% had 2-year biochemical control. Forty-two patients (23%) had a stable or rising interim PSA, and only 24% of these patients had 2-year biochemical control. On multivariate analysis, a drop in PSA during radiation therapy (P < .0001) and a positive surgical margin (P < .0001) were significant factors for freedom from subsequent biochemical failure, and seminal vesicle invasion was associated with biochemical failure at 2 years (P = .019). All patients with a rising interim PSA, negative surgical margin, and seminal vesicle invasion ultimately had biochemical failure at 2 years. CONCLUSIONS: A PSA rise during salvage radiation therapy is prognostic of biochemical failure at 2 years. Factors such as seminal vesicle invasion and a negative surgical margin also predict for poor responders to salvage radiation therapy.
format Online
Article
Text
id pubmed-8071726
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80717262021-04-27 Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy Cardoso, Michael Ngo, Diana Lim, Karen Wong, Karen Sidhom, Mark Adv Radiat Oncol Scientific Article PURPOSE: A subset of patients treated with postprostatectomy radiation therapy for biochemical recurrence after surgery fail to respond because of microscopic disease beyond the irradiated prostate bed. This work aims to determine whether a rising interim prostate-specific antigen (PSA) during radiation therapy can predict the likelihood of subsequent biochemical recurrence. METHODS AND MATERIALS: Between 2010 and 2016, 185 patients had salvage radiation therapy to a dose of 68 Gy without androgen deprivation therapy for a rising PSA level after radical prostatectomy. Patients had their PSA recorded on the first day of radiation therapy and again after completing the 25th fraction (of 34 total fractions). Biochemical failure after radiation therapy was defined as a PSA value ≥0.2 ng/mL within 2 years after radiation therapy. Both univariate and multivariate Cox regression models were used for statistical analysis. Factors with a P value of <.2 in univariate analysis were then used in a multivariate analysis. RESULTS: The 2-year freedom from biochemical failure was 60% (95% confidence interval, 53%-67%). When assessing the interim PSA, 143 patients (77%) had a drop in interim PSA; of these patients, 71% had 2-year biochemical control. Forty-two patients (23%) had a stable or rising interim PSA, and only 24% of these patients had 2-year biochemical control. On multivariate analysis, a drop in PSA during radiation therapy (P < .0001) and a positive surgical margin (P < .0001) were significant factors for freedom from subsequent biochemical failure, and seminal vesicle invasion was associated with biochemical failure at 2 years (P = .019). All patients with a rising interim PSA, negative surgical margin, and seminal vesicle invasion ultimately had biochemical failure at 2 years. CONCLUSIONS: A PSA rise during salvage radiation therapy is prognostic of biochemical failure at 2 years. Factors such as seminal vesicle invasion and a negative surgical margin also predict for poor responders to salvage radiation therapy. Elsevier 2021-01-16 /pmc/articles/PMC8071726/ /pubmed/33912736 http://dx.doi.org/10.1016/j.adro.2021.100646 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Cardoso, Michael
Ngo, Diana
Lim, Karen
Wong, Karen
Sidhom, Mark
Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy
title Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy
title_full Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy
title_fullStr Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy
title_full_unstemmed Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy
title_short Interim Prostate-Specific Antigen: Predicting for Biochemical Failure During Salvage Radiation Therapy After Prostatectomy
title_sort interim prostate-specific antigen: predicting for biochemical failure during salvage radiation therapy after prostatectomy
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071726/
https://www.ncbi.nlm.nih.gov/pubmed/33912736
http://dx.doi.org/10.1016/j.adro.2021.100646
work_keys_str_mv AT cardosomichael interimprostatespecificantigenpredictingforbiochemicalfailureduringsalvageradiationtherapyafterprostatectomy
AT ngodiana interimprostatespecificantigenpredictingforbiochemicalfailureduringsalvageradiationtherapyafterprostatectomy
AT limkaren interimprostatespecificantigenpredictingforbiochemicalfailureduringsalvageradiationtherapyafterprostatectomy
AT wongkaren interimprostatespecificantigenpredictingforbiochemicalfailureduringsalvageradiationtherapyafterprostatectomy
AT sidhommark interimprostatespecificantigenpredictingforbiochemicalfailureduringsalvageradiationtherapyafterprostatectomy